Pinealon.
Pinealon (Glu-Asp-Arg) is a synthetic tripeptide bioregulator developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, derived from pineal gland tissue and studied for neuroprotection, circadian modulation, and cognitive aging.
- Key Signals
- Neuroprotection · Cognitive Aging · Circadian
- Origin
- Synthetic (pineal gland tissue-derived)
- Investigator
- Khavinson et al. (IB&G St. Petersburg), 2000s
- Class
- Neuroprotective tripeptide bioregulator
- Status (UAE)
- Research compound (off-label)
The Pineal Gland's Signal, Three Residues at a Time
Khavinson's group derives Pinealon from pineal gland extracts at the St. Petersburg IB&G as a short tripeptide bioregulator.
Preclinical models of ischaemia and oxidative stress show neuroprotection, BDNF upregulation, and improved neuronal survival.
Research expands into retinal protection and cognitive aging, where Pinealon is investigated for epigenetic gene regulation and circadian modulation.
Three residues, one neuroprotective signal.
Glu-Asp-Arg
C₁₅H₂₆N₆O₈ · MW 418.4 Da
Pinealon maps to the Glu-Asp-Arg sequence from pineal gland tissue, proposed to modulate neuronal gene expression through chromatin interaction — the central mechanism in the Khavinson bioregulator model.
IB&G data only, no independent replication.
All published data originates from Khavinson's group; no independent peer-reviewed replication exists for any indication.
- Neuroprotection in ischaemia models
- BDNF upregulation confirmed (IB&G)
- Retinal photoreceptor protection
- Oxidative stress reduction
- Anti-apoptotic activity shown
- Cognitive scores improved (small n)
- Sleep quality improvement reported
- No independent trial replication
- Supplement-grade, not drug-grade data
- Epigenetic anti-aging mechanisms
- Melatonin pathway modulation
- DNA repair and longevity signals
- Circadian rhythm restoration
Sign in to view the full research brief.
Mechanism deep-dive and research dosing protocols — available to registered researchers. It's free and takes under a minute.
A Russian Supplement, Not a Drug
In the UAE, research-grade peptides occupy a defined regulatory category distinct from licensed medicines. Compounds sold under this classification — including those offered by Dubai Peptides — are intended exclusively for qualified research applications, not for human administration.
Pinealon has no drug approval in any jurisdiction. It is sold as a food supplement in Russia by the IB&G group, which does not constitute regulatory approval. No IND or marketing authorisation has been filed in the US, EU, or UAE. All published human data originates from the same investigator group that developed and markets the compound — no independent peer-reviewed replication exists.
Khavinson's group at the St. Petersburg IB&G develops Pinealon as part of a programme of short tripeptide bioregulators derived from organ-specific tissue extracts.
Preclinical studies report neuroprotective and retinal-protective effects, establishing the compound's research profile across ischaemia and oxidative stress models.
Pinealon enters the Russian supplement market through the IB&G's Peptides.ru platform — sold as a bioregulator rather than a pharmaceutical.